The Effect of GDNF on Nigrostriatal Dopaminergic Function in Response to a Two-Pulse K+ Stimulation

Xu, Kui; Dluzen, Dean E.

doi:10.1006/exnr.2000.7515

Cited by 17 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the effects observed on evoked DA overflow and tissue levels of DA are similar to what has been reported in rats treated with GDNF. For example, following the injection of a single dose of GDNF into the brain of unlesioned rats, previous studies have reported increases, or a trend for an increase, in potassium-evoked overflow of striatal DA (Cass and Manning, 1999; Cass and Peters, 2010; Hebert et al, 1996; Hebert and Gerhardt, 1997; Xu and Dluzen, 2000), and increases in amphetamine-evoked overflow of striatal DA (Cass and Peters, 2010; Hebert et al, 1996; Hebert and Gerhardt, 1997). In addition, tissue levels of DA in the substantia nigra are also significantly increased following a single intracerebral administration of GDNF (Cass and Manning 1999; Cass and Peters, 2010; Hebert et al, 1996; Hudson et al, 1995; Martin et al, 1996).…”

Section: Discussionmentioning

confidence: 99%

“…These effects include changes in tissue levels of DA in the nigrostriatal system (Cass and Peters, 2010; Hudson et al, 1995; Martin et al, 1996;), augmentation of stimulus-evoked overflow of DA from the striatum (Hebert et al, 1996; Xu and Dluzen, 2000), and behavioral changes that suggest activation of dopaminergic systems (Hudson et al, 1995; Kobayashi et al, 1998; Martin et al, 1996). Similar changes have been reported in aged animals following acute or chronic administration of GDNF (Emerich et al, 1996; Grondin et al, 2003; Hebert and Gerhardt, 1997; Lapchak et al, 1997).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats

Cass

Peters

Fletcher

et al. 2012

Neurochemistry International

View full text Add to dashboard Cite

Calcitriol, the active metabolite of vitamin D, has been shown to have significant effects on the brain. These actions include reducing the severity of some central nervous system lesions, possibly by upregulating trophic factors such as glial cell line-derived neurotrophic factor (GDNF). GDNF has substantial effects on the nigrostriatal dopamine (DA) system of young adult, aged and lesioned animals. Thus, the administration of calcitriol may lead to significant effects on nigrostriatal DA neuron functioning. The present experiments were designed to examine the ability of calcitriol to alter striatal DA release, and striatal and nigral tissue levels of DA. Male Fischer-344 rats were administered vehicle or calcitriol (0.3, 1.0, or 3.0 μg/kg, s.c.) once daily for 8 consecutive days. Three weeks later in vivo microdialysis experiments were conducted to measure basal and stimulus evoked overflow of DA from the striatum. Basal levels of extracellular DA were not significantly affected by the calcitriol treatments. However, the 1.0 and 3.0 μg/kg doses of calcitriol led to increases in both potassium and amphetamine evoked overflow of striatal DA. Although post-mortem tissue levels of striatal DA were not altered by the calcitriol injections, nigral tissue levels of DA and its main metabolites were increased by both the 1.0 and 3.0 μg/kg doses of calcitriol. In a separate group of animals GDNF levels were augmented in the striatum and substantia nigra after eight consecutive daily injections of calcitriol. These results suggest that systemically administered calcitriol can upregulate dopaminergic release processes in the striatum and DA levels in the substantia nigra. Increases in levels of endogenous GDNF following calcitriol treatment may in part be responsible for these changes. The ability of calcitriol to lead to augmented DA release in the striatum suggests that calcitriol may be beneficial in disease processes involving dopaminergic dysfunction.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats

Cass

Peters

Fletcher

et al. 2012

Neurochemistry International

View full text Add to dashboard Cite

show abstract

“…Previous in vivo studies in rats have reported increases in both potassium- and amphetamine-evoked overflow of striatal DA following intranigral GDNF [3, 9], a trend for an increase in potassium-evoked overflow following intranigral GDNF [21], and an increase in potassium-evoked overflow following intrastriatal GDNF [4]. The present study found a significant increase in amphetamine-evoked overflow of DA in the striatum, and a trend for an increase in potassium-evoked overflow of DA.…”

Section: Discussionmentioning

confidence: 99%

“…In young adult animals these effects include increases in DA levels in the substantia nigra [1, 2], increases in evoked overflow of DA from the striatum [3, 4], changes in expression and phosphorylation of tyrosine hydroxylase (TH) [5, 6] and changes in behaviors thought to involve dopaminergic activation [1, 2, 7]. Similar neurochemical and behavioral effects have been reported in aged animals [8–11].…”

Section: Introductionmentioning

confidence: 91%

“…Similar to GDNF, NTN has potent effects on normal DA neurons both in vitro [13–15] and in vivo [13, 16, 17]. However, while the intracerebral administration of GDNF leads to increases in stimulus evoked DA overflow in the striatum of normal animals [3, 4], the ability of NTN to produce functional effects on DA release has not been previously reported. While some studies have reported similarities between the effects of NTN and GDNF on the nigrostriatal DA system [14], there are reports of differences as well [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neurturin Effects on Nigrostriatal Dopamine Release and Content: Comparison with GDNF

Cass

Peters

2010

Neurochem Res

View full text Add to dashboard Cite

Neurturin (NTN) is a member of the glial cell line-derived neurotrophic factor (GDNF) family; and, while GDNF has been shown to increase dopamine (DA) release in normal animals, the ability of NTN to alter DA release has not been previously reported. The purpose of the present study was to determine if NTN could alter striatal DA release, and to compare the effects of NTN to GDNF. Male Fischer-344 rats were given a single injection of vehicle or 5 μg NTN or GDNF into the right substantia nigra. Three weeks later microdialysis experiments were conducted to assess striatal DA release. Basal extracellular levels of striatal DA were not affected by either NTN or GDNF. However, both NTN and GDNF led to increases in amphetamine-evoked overflow of DA from the ipsilateral striatum, and there was a trend for potassium-evoked overflow to be augmented. Postmortem tissue levels of DA were decreased by approximately 20% in the striatum, and increased by approximately 100% in the substantia nigra, on the ipsilateral side of the brain compared to the contralateral side following both NTN and GDNF injection. Thus, NTN, like GDNF, can augment striatal DA release, and the magnitude of the NTN effects are similar to those of GDNF.

show abstract

Reversible neurochemical changes mediated by delayed intrastriatal glial cell line‐derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model

Yang

Mertens

Lehtonen

et al. 2009

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

The Effect of GDNF on Nigrostriatal Dopaminergic Function in Response to a Two-Pulse K+ Stimulation

Cited by 17 publications

References 24 publications

Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats

Evoked dopamine overflow is augmented in the striatum of calcitriol treated rats

Neurturin Effects on Nigrostriatal Dopamine Release and Content: Comparison with GDNF

Reversible neurochemical changes mediated by delayed intrastriatal glial cell line‐derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model

Contact Info

Product

Resources

About